Atrioventricular nodal ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy
Heart Rhythm · 2023
DOI: 10.1016/j.hrthm.2023.08.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm, 2023. Verfasst von Charles Butcher und 15 weiteren Autor:innen. Beteiligte Einrichtung: Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Catheter Ablation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: British Heart Foundation, Abbott Laboratories, Medtronic.
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and can be challenging to manage. Atrioventricular nodal (AVN) ablation may be an effective management strategy for AF in these patients. OBJECTIVE: The purpose of this study was to assess the efficacy of AVN ablation in HCM patients who have failed medical therapy and/or catheter ablation for AF. METHODS: A multicenter study with retrospective analysis of a prospectively collated HCM registry was performed. AVN ablation patients were identified. Baseline characteristics and device and procedural indications were collected. Symptoms defined by New York Heart Association and European Heart Rhythm Association classification and echocardiographic findings during follow-up were assessed. RESULTS: Fifty-nine patients were included in the study. Indications for AVN ablation were 6 (10.2%) inappropriate implantable cardioverter-defibrillator shock, 35 (59.3%) ineffective rate control, and 18 (30.5%) to regularize rhythm for symptom improvement. During post-AVN ablation follow-up of 79.4 ± 61.1 months, left ventricular ejection fraction (LVEF) remained stable (pre-LVEF 48.9% ± 12.6% vs post-LVEF 50.1% ± 10.1%; P = .29), even in those without a cardiac resynchronization therapy (CRT) device (pre-LVEF 54.3% ± 8.0% vs post-LVEF 53.8% ± 8.0%; P = .65). Forty-nine patients (83.1%) reported an improvement in symptoms regardless of AF type (17/21 [81.0%] paroxysmal vs 32/38 [84.2%] persistent; P = 1.00), presence of baseline left ventricular impairment (22/26 [84.6%] LVEF ≤50% vs 27/33 [81.8%] LVEF ≥50%; P = 1.00) or CRT device (27/32 [84.4%] CRT vs 22/27 [81.5%] no CRT; P = 1.00). Symptoms improved in 16 patients (89.0%) who underwent AVN ablation to regularize rhythm. CONCLUSION: AVN ablation improved symptoms without impacting left ventricular function in the majority of patients. The data suggest that AVN ablation is an effective and safe management approach for AF in HCM and should be further evaluated in larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
- University College London Medical School, London, United Kingdom.
- University Hospital Southampton, London, United Kingdom.
- Royal Brompton and Harefield NHS Trusts, London, United Kingdom.
- John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
- Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Förderung
- British Heart Foundation
- Abbott Laboratories
- Medtronic
Zitieren
APA
Butcher, C., Rajappan, S., Wharmby, A. L., Ullah, W., Wong, T., Jones, D., Rajappan, K., Martin, C., Elliott, P., Gill, J. S., Specterman, M., Dhinoja, M. B., Sporton, S., Lambiase, P. D., Hunter, R. J., & Honarbakhsh, S. (2023). Atrioventricular nodal ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2023.08.028
Vancouver
Butcher C, Rajappan S, Wharmby AL, Ullah W, Wong T, Jones D, et al. Atrioventricular nodal ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm. 2023. doi:10.1016/j.hrthm.2023.08.028
BibTeX
@article{Butcher2023,
author = {Butcher, Charles and Rajappan, Saffron and Wharmby, Amy L and Ullah, Waqas and Wong, Tom and Jones, David and Rajappan, Kim and Martin, Claire and Elliott, Perry and Gill, Jaspal Singh and Specterman, Mark and Dhinoja, Mehul B and Sporton, Simon and Lambiase, Pier D and Hunter, Ross J and Honarbakhsh, Shohreh},
title = {Atrioventricular nodal ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy},
journal = {Heart Rhythm},
year = {2023},
doi = {10.1016/j.hrthm.2023.08.028}
}
EUVIMED